In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fujirebio Inc.

Division of Miraca Holdings Inc.

Latest From Fujirebio Inc.

Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer

The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.

Market Intelligence Cancer

Unsuccessful IPOs

Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.

BioPharmaceutical Deals

Fujirebio snaps up offloaded Abbott diagnostics unit

The Japanese firm Fujirebio is to pay ¥9.8 billion ($112.9 million) for Innogenetics, a Belgian diagnostics and biologics operation acquired by Abbott as part of the US firm's broader purchase of Solvay Pharmaceuticals earlier this year.

Brazil Deals

Clinical Edge

Brief summaries of recent advances in device research and clinical trials, including a new study sugesting that treating post-PCI patients with vascular closure devices in combination with bivalirudin have substantially reduced bleeding rates, and a large study of postmeenopausal women indicated that tracking CA-125 may be an effective way to detect early-stage ovarian cancer.

Medical Device
See All

Company Information